Corcept Therapeutics

Corcept is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.

Relacorilant (Lifyorli) in platinum-resistant ovarian cancer (ROSELLA) and Cushing's syndrome.

Headquarters

Redwood City, CA, US

Type

biotech · CORT

Website

Products

A first-in-class drug that blocks cortisol signalling in tumour cells, approved in 2026 for platinum-resistant ovarian cancer with chemotherapy.

not linked directly; found by shared links